Mackenzie Financial Corp Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mackenzie Financial Corp lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 493.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,286 shares of the specialty pharmaceutical company's stock after purchasing an additional 16,867 shares during the quarter. Mackenzie Financial Corp's holdings in Jazz Pharmaceuticals were worth $2,498,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $25,000. Quadrant Capital Group LLC raised its stake in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares during the period. Elequin Capital LP lifted its holdings in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. CoreFirst Bank & Trust acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $28,000. Finally, Allianz SE purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $29,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Needham & Company LLC reissued a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday. Robert W. Baird cut their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Truist Financial raised their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Barclays reaffirmed an "overweight" rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $182.93.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan acquired 100,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 9th. The stock was acquired at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the transaction, the director now owns 100,000 shares of the company's stock, valued at $9,826,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now directly owns 82,024 shares in the company, valued at $11,368,526.40. This trade represents a 7.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,123 shares of company stock worth $1,772,966 over the last ninety days. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Up 1.9%

NASDAQ:JAZZ traded up $2.03 during mid-day trading on Tuesday, hitting $110.32. The stock had a trading volume of 702,054 shares, compared to its average volume of 839,524. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a 50-day simple moving average of $108.95 and a two-hundred day simple moving average of $121.18. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $6.80 billion, a PE ratio of 15.54, a PEG ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. Jazz Pharmaceuticals's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.68 earnings per share. On average, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.